HUP1700253A1 - Szilárd orális gyógyszerkészítmények - Google Patents

Szilárd orális gyógyszerkészítmények

Info

Publication number
HUP1700253A1
HUP1700253A1 HUP1700253A HUP1700253A1 HU P1700253 A1 HUP1700253 A1 HU P1700253A1 HU P1700253 A HUP1700253 A HU P1700253A HU P1700253 A1 HUP1700253 A1 HU P1700253A1
Authority
HU
Hungary
Prior art keywords
oral administration
solid preparations
preparations
solid
oral
Prior art date
Application number
Other languages
English (en)
Hungarian (hu)
Inventor
Konta Melinda Dr
Edit Suba
Tuende Beata Daroczi
Zoltan Magos
Labos Ramona Rajszkine
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Priority to HUP1700253 priority Critical patent/HUP1700253A1/hu
Priority to TW107118464A priority patent/TW201906608A/zh
Priority to CN201880040070.6A priority patent/CN110769815A/zh
Priority to BR112019025214-2A priority patent/BR112019025214A2/pt
Priority to PE2019002491A priority patent/PE20200334A1/es
Priority to CA3064694A priority patent/CA3064694A1/en
Priority to MX2019015206A priority patent/MX2019015206A/es
Priority to PCT/IB2018/054227 priority patent/WO2018229641A1/en
Priority to KR1020207001040A priority patent/KR20200016378A/ko
Priority to EP18734306.6A priority patent/EP3638210A1/en
Priority to AU2018284138A priority patent/AU2018284138A1/en
Priority to JP2019568138A priority patent/JP2020523335A/ja
Priority to EA202090029A priority patent/EA202090029A1/ru
Priority to US16/622,020 priority patent/US20200222391A1/en
Priority to ARP180101591A priority patent/AR112137A1/es
Publication of HUP1700253A1 publication Critical patent/HUP1700253A1/hu
Priority to PH12019502566A priority patent/PH12019502566A1/en
Priority to IL271108A priority patent/IL271108A/en
Priority to CL2019003619A priority patent/CL2019003619A1/es
Priority to ZA2019/08454A priority patent/ZA201908454B/en
Priority to CONC2020/0000168A priority patent/CO2020000168A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HUP1700253 2017-06-13 2017-06-13 Szilárd orális gyógyszerkészítmények HUP1700253A1 (hu)

Priority Applications (20)

Application Number Priority Date Filing Date Title
HUP1700253 HUP1700253A1 (hu) 2017-06-13 2017-06-13 Szilárd orális gyógyszerkészítmények
TW107118464A TW201906608A (zh) 2017-06-13 2018-05-30 口服固體製劑
EP18734306.6A EP3638210A1 (en) 2017-06-13 2018-06-12 Solid preparation of cariprazine for oral administration
JP2019568138A JP2020523335A (ja) 2017-06-13 2018-06-12 経口投与用固形製剤
PE2019002491A PE20200334A1 (es) 2017-06-13 2018-06-12 Preparacion solida para administracion oral
CA3064694A CA3064694A1 (en) 2017-06-13 2018-06-12 Solid preparation of cariprazine for oral administration
MX2019015206A MX2019015206A (es) 2017-06-13 2018-06-12 Preparacion solida de cariprazina para administracion oral.
PCT/IB2018/054227 WO2018229641A1 (en) 2017-06-13 2018-06-12 Solid preparation of cariprazine for oral administration
KR1020207001040A KR20200016378A (ko) 2017-06-13 2018-06-12 경구 투여를 위한 카리프라진의 고체 제제
CN201880040070.6A CN110769815A (zh) 2017-06-13 2018-06-12 口服的卡利拉嗪固体制剂
AU2018284138A AU2018284138A1 (en) 2017-06-13 2018-06-12 Solid preparation of cariprazine for oral administration
BR112019025214-2A BR112019025214A2 (pt) 2017-06-13 2018-06-12 Composição farmacêutica sólida administrável por via oral, uso da composição farmacêutica, processo para a preparação de composições farmacêuticas, e, método de tratamento de um paciente que sofre de condições patológicas
EA202090029A EA202090029A1 (ru) 2017-06-13 2018-06-12 Твердая композиция карипразина для орального введения
US16/622,020 US20200222391A1 (en) 2017-06-13 2018-06-12 Solid preparation of cariprazine for oral administration
ARP180101591A AR112137A1 (es) 2017-06-13 2018-06-12 Preparación sólida para administración oral que comprende cariprazina
PH12019502566A PH12019502566A1 (en) 2017-06-13 2019-11-15 Pharmacologically active alicyclic-substituted pyrazolo[1,5-a] pyrimidine derivatives
IL271108A IL271108A (en) 2017-06-13 2019-12-02 A solid preparation of cariprazine for oral administration
CL2019003619A CL2019003619A1 (es) 2017-06-13 2019-12-11 Preparación sólida para administración oral.
ZA2019/08454A ZA201908454B (en) 2017-06-13 2019-12-18 Solid preparation of cariprazine for oral administration
CONC2020/0000168A CO2020000168A2 (es) 2017-06-13 2020-01-09 Preparación sólida de cariprazina para administración oral

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HUP1700253 HUP1700253A1 (hu) 2017-06-13 2017-06-13 Szilárd orális gyógyszerkészítmények

Publications (1)

Publication Number Publication Date
HUP1700253A1 true HUP1700253A1 (hu) 2019-01-28

Family

ID=89992469

Family Applications (1)

Application Number Title Priority Date Filing Date
HUP1700253 HUP1700253A1 (hu) 2017-06-13 2017-06-13 Szilárd orális gyógyszerkészítmények

Country Status (20)

Country Link
US (1) US20200222391A1 (enExample)
EP (1) EP3638210A1 (enExample)
JP (1) JP2020523335A (enExample)
KR (1) KR20200016378A (enExample)
CN (1) CN110769815A (enExample)
AR (1) AR112137A1 (enExample)
AU (1) AU2018284138A1 (enExample)
BR (1) BR112019025214A2 (enExample)
CA (1) CA3064694A1 (enExample)
CL (1) CL2019003619A1 (enExample)
CO (1) CO2020000168A2 (enExample)
EA (1) EA202090029A1 (enExample)
HU (1) HUP1700253A1 (enExample)
IL (1) IL271108A (enExample)
MX (1) MX2019015206A (enExample)
PE (1) PE20200334A1 (enExample)
PH (1) PH12019502566A1 (enExample)
TW (1) TW201906608A (enExample)
WO (1) WO2018229641A1 (enExample)
ZA (1) ZA201908454B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009270823B2 (en) 2008-07-16 2014-07-17 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US11344503B2 (en) 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations
US20230355612A1 (en) * 2020-08-26 2023-11-09 Shanghai Bocimed Pharmaceutical Co., Ltd. Pharmaceutically acceptable salt of cariprazine and crystal form thereof, and preparation method therefor and use thereof
CN114681406B (zh) * 2020-12-25 2023-10-13 上海京新生物医药有限公司 一种卡利拉嗪长效缓释微球及其制备方法
CN114748428B (zh) * 2020-12-25 2023-05-23 上海京新生物医药有限公司 一种高载药量的盐酸卡利拉嗪长效缓释微球及其制备方法
CN116675654B (zh) * 2022-02-22 2025-06-13 上海云晟研新生物科技有限公司 卡利拉嗪药用盐及其晶型、药物组合物、制备方法和用途
CA3244202A1 (en) 2022-03-17 2023-09-21 Mapi Pharma Ltd. DEPOSIT SYSTEMS INCLUDING CARIPRAZINE OR SALTS THEREOF
HU231682B1 (hu) * 2022-08-05 2025-10-28 Richter Gedeon Nyrt. Kariprazin tartalmú szájban diszpergálódó tabletta
TR2024011970A1 (tr) * 2024-09-10 2026-03-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Kari̇prazi̇n hi̇droklorür i̇çeren kati bi̇r oral bi̇leşi̇m
TR2024011968A1 (tr) * 2024-09-10 2026-03-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Kariprazin hidroklorür içeren kapsül formülasyonlari

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6248618A (ja) * 1985-08-27 1987-03-03 Zeria Shinyaku Kogyo Kk 徐放性製剤およびその製造法
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
ES2653852T3 (es) * 2007-08-03 2018-02-09 Richter Gedeon Nyrt. Composiciones farmacéuticas que contienen ligandos del receptor de dopamina y procedimientos de tratamiento usando ligandos del receptor de dopamina
CA2715760C (en) 2008-02-21 2017-06-13 Mitsubishi Tanabe Pharma Corporation Solid preparation for oral administration of cariprazine hydrochloride
AU2009270823B2 (en) 2008-07-16 2014-07-17 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
MX2016010213A (es) * 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Formulaciones farmaceuticas novedosas.
CN106692149A (zh) * 2015-11-13 2017-05-24 天津市汉康医药生物技术有限公司 一种卡利拉嗪药物口服制剂及其制备方法

Also Published As

Publication number Publication date
ZA201908454B (en) 2021-10-27
BR112019025214A2 (pt) 2020-06-16
AU2018284138A1 (en) 2020-01-16
MX2019015206A (es) 2020-02-10
JP2020523335A (ja) 2020-08-06
CO2020000168A2 (es) 2021-06-21
EP3638210A1 (en) 2020-04-22
PH12019502566A1 (en) 2020-07-20
CN110769815A (zh) 2020-02-07
US20200222391A1 (en) 2020-07-16
CL2019003619A1 (es) 2020-05-15
EA202090029A1 (ru) 2020-03-26
KR20200016378A (ko) 2020-02-14
AR112137A1 (es) 2019-09-25
CA3064694A1 (en) 2018-12-20
WO2018229641A1 (en) 2018-12-20
TW201906608A (zh) 2019-02-16
IL271108A (en) 2020-01-30
PE20200334A1 (es) 2020-02-14

Similar Documents

Publication Publication Date Title
PL3720496T3 (pl) Stały doustny preparat nikotynowy
GB201807942D0 (en) Pharmaceutical formulation
IL270812A (en) Solid compositions for oral drug administration
ZA201908454B (en) Solid preparation of cariprazine for oral administration
ZA201903101B (en) Pharmaceutical formulations
IL278927A (en) pharmaceutical preparation
IL283450A (en) capsule formulations
ZA202102871B (en) Pharmaceutical formulation
IL262745A (en) Improved preparations containing drugs
ZA202006570B (en) Pharmaceutical formulations
IL262204A (en) Granular formulation for oral administration
HUE061697T2 (hu) Stabil gyógyszerkészítmény orális adagolásra
EP3290037A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
SG11202010792TA (en) Improved pharmaceutical formulations
IL271908A (en) Over-compressed pharmaceutical preparations
PT3684407T (pt) Formulações farmacêuticas para adalimumab
EP3512507A4 (en) ORAL MEDICINAL FORMULATIONS
ZA202006346B (en) Pharmaceutical preparation
EP3162368A4 (en) Pharmaceutical composition for oral administration
PL3996688T3 (pl) Preparat farmaceutyczny
PT3377044T (pt) Composições de ibuprofeno para administração oral direta
HK40020415A (en) Solid preparation of cariprazine for oral administration
HK40009162A (en) Pharmaceutical formulations
GB201610440D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished